TY - JOUR T1 - Disrupted white matter integrity in treatment-resistant schizophrenia JF - medRxiv DO - 10.1101/19010777 SP - 19010777 AU - Carolyn B. McNabb AU - Meghan E. McIlwain AU - Valerie M. Anderson AU - Robert R. Kydd AU - Frederick Sundram AU - Bruce R. Russell Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/12/11/19010777.abstract N2 - Treatment response in schizophrenia is heterogeneous and has been posited to divide into three distinct subcategories: treatment-responsive (first-line responders; FLR), treatment-resistant (TRS, responding to clozapine), and ultra-treatment-resistant schizophrenia (UTRS, requiring augmented antipsychotic therapy). Previous work suggests that white matter abnormalities drive antipsychotic resistance but little work has been carried out to identify differences between those with TRS and those with UTRS. The current study aimed to establish whether differences in white matter structure are present across both treatment-resistant subtypes of schizophrenia or if UTRS is distinct from TRS. Diffusion-weighted images were acquired for 18 individuals with TRS, 14 with UTRS, 18 FLR and 20 healthy controls. Measures of fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD) and parallel diffusivity (PD) were obtained using tract-based spatial statistics. Analysis of variance (ANOVA) and post-hoc between-groups t-tests interrogating differences were conducted for each white matter measure. Those with TRS had lower FA than healthy controls across widespread regions of the brain, including the superior longitudinal fasciculus, corpus callosum, thalamic radiation, corticospinal tract, internal capsule, corona radiata and fronto-occipital fasciculus (p<.05 FWE-corrected). Lower FA was also observed in those with TRS compared with UTRS in the superior longitudinal fasciculus (p<.05 FWE-corrected). However, post-hoc tests failed to survive corrections for multiple comparisons across the 12 post-hoc contrasts. No differences in MD, PD or RD were observed between groups. These data suggest that TRS is distinct from UTRS and that lower FA could act as a biomarker of treatment resistance in people with schizophrenia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The University of Auckland Faculty Research and Development Fund, with support from the New Zealand Schizophrenia Research Group and the Oakley Mental Health Research Foundation. Meghan McIlwain was supported by a University of Auckland Doctoral Scholarship and a New Zealand Federation of Graduate Women Fellowship. Valerie Anderson was supported by an Edith C. Coan Research Fellowship from The Auckland Medical Research Foundation. No funders had any role in the study design; in the collection, analysis or interpretation of data; in the writing of the report; or in the decision to submit the article for publication. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis data is confidential and cannot be shared ER -